Al­ny­lam seeks com­pen­sa­tion from Mod­er­na and Pfiz­er in suits over patent­ed de­liv­ery of their Covid-19 vac­cines

RNAi ther­a­peu­tics jug­ger­naut Al­ny­lam Phar­ma­ceu­ti­cals on Thurs­day an­nounced that it’s su­ing and seek­ing mon­ey from both Pfiz­er and Mod­er­na re­gard­ing their use of Al­ny­lam’s biodegrad­able lipids, which have been in­te­gral to the way both com­pa­nies’ mR­NA vac­cines work.

The suits, filed in the Delaware dis­trict court, both seek “fair com­pen­sa­tion for use of its tech­nol­o­gy” but “no less than a rea­son­able roy­al­ty.” And if suc­cess­ful, the biotech will dip in­to two of the rich­est rev­enue streams the bio­phar­ma in­dus­try has ever seen.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.